Loading rounds…
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| WG WhiteLab GenomicsCompany profile WhiteLab Genomics uses AI to design genetic medicines and develop bio-assets for cell, RNA and DNA therapies. WhiteLab Genomics uses AI to design genetic medicines and develop bio-assets for cell, RNA and DNA therapies. | $26M | Series B | Biotech | United States | Investors | |
| AS |
Ranked by rounds participated in · All time
AusperBio, Abcuro, Infinimmune
Epicrispr Biotechnologies, Draig Therapeutics, Triveni Bio
LifeMine Therapeutics, Ollin Biosciences, SonoThera
Leal Therapeutics, Khartis Therapeutics, Vedana Therapeutics
Leal Therapeutics, Amplifica Holdings Group, InduPro
Explore published rounds while the next edition is being prepared.
Autopoiesis Sciences is developing AI research tools that help scientists plan and carry out scientific discovery.
Autopoiesis Sciences is developing AI research tools that help scientists plan and carry out scientific discovery.
| $11M |
| Seed |
| Biotech |
| — |
| Investors |
| SB Sensible BiotechnologiesCompany profile A platform for designing and manufacturing naturally modified mRNA medicines. A platform for designing and manufacturing naturally modified mRNA medicines. | $47M | Series A | Biotech | United Kingdom | Investors |
AventixCompany profile Aventix builds sensor-based analytical instruments for laboratories. Its first product, Scarlett 01, measures liquid volumes across microplate wells without touching the sample, helping R&D teams check dispensing quality and catch volume variation before it affects assay results. Aventix builds sensor-based analytical instruments for laboratories. Its first product, Scarlett 01, measures liquid volumes across microplate wells without touching the sample, helping R&D teams check dispensing quality and catch volume variation before it affects assay results. | €1.2M | Pre-seed | Biotech | Sweden | Investors |
AnaCardioCompany profile AnaCardio is a clinical-stage biopharmaceutical company developing medicines intended to improve heart muscle function in people with heart failure. AnaCardio is a clinical-stage biopharmaceutical company developing medicines intended to improve heart muscle function in people with heart failure. | €62.5M | Series B | Biotech | Sweden | Investors |
| AT Aptadir TherapeuticsCompany profile RNA therapeutics designed to restore expression of silenced genes RNA therapeutics designed to restore expression of silenced genes | €40M | Seed | Biotech | Italy | Investors |
| MB MOYOM BiotechCompany profile Develops absorbable biomaterials and implantable medical devices for regenerative aesthetic treatments. Develops absorbable biomaterials and implantable medical devices for regenerative aesthetic treatments. | Undisclosed | Financing roundUndisclosed | Biotech, Healthtech | China | Investors |
| W WonderTxCompany profile AI models designed to discover oral medicines for diseases currently treated with injectable drugs. AI models designed to discover oral medicines for diseases currently treated with injectable drugs. | $125K | Seed | Biotech | United States | Investors |
| EB Everest BiolabsCompany profile Automated instruments and assays that help biomedical researchers isolate and analyze extracellular vesicles from biological samples. Automated instruments and assays that help biomedical researchers isolate and analyze extracellular vesicles from biological samples. | $2.1M | SBIR Direct-to-Phase II grantUndisclosed | Biotech | United States | Investors |
| UI United ImmunityCompany profile A biotechnology company developing nanoparticle delivery systems and immunotherapies that target macrophages and dendritic cells in diseased tissue. A biotechnology company developing nanoparticle delivery systems and immunotherapies that target macrophages and dendritic cells in diseased tissue. | ¥2.2B | Private financingUndisclosed | Biotech | Japan | Investors Aozora HYBRID Fund IIIFujita TT Impact Fund I +11ITOCHU CorporationJoyo Bank, Ltd.Kobe University Fund IMitsubishi UFJ Life Sciences Fund IIMiyako Kyoto University Innovation Fund IIIMizuho Life Sciences Fund INVCC Fund 10Ono Venture Investment, Inc.Ricoh Biomedical Startup Investment Limited PartnershipSaisei Bioventures L.P.UTEC Fund V Limited Partnership |